1. The strategy of comprehensively upgrading t2b2c of pharmaceutical network is proposed to build an all channel commercial platform

Securities Times reporter Mei Shuang On December 11, the second China Internet medicine health summit forum and the Partner Conference of Internet medicine network 1 (NASDAQ: Yi) were held in Shanghai At the meeting, 1 pharmaceutical network comprehensively upgraded the t2b2c strategy, put forward for the first time to build an all-channel commercial platform, and launched the original research drug welfare plan for the C-end to help pharmaceutical enterprises cope with the post "4 + 7" era In 2019, in 2019, with the volume of procurement from the pilot expansion of the country, the pharmaceutical industry ushered in epoch-making changes At the conference, Dr Yu Gang, co-founder and executive chairman of 1 pharmaceutical network, and Liu Junling, co-founder and chairman and CEO of 1 pharmaceutical network, comprehensively elaborated the omni channel commercialization platform strategy of 1 pharmaceutical network for pharmaceutical enterprises According to the introduction, after one year's practice and exploration, this year 1 pharmaceutical network has comprehensively upgraded the t2b2c strategy In addition to further enriching the empowering system of pharmaceutical enterprises, pharmacies, patients and insurance enterprises, it has also added an organizational empowering system, and formally put forward a full life cycle management scheme for patients Through CRM system, we can provide all-round patient management services, enhance service stickiness, improve medication compliance, and improve the continuation rate With the expansion of volume procurement, the future market will be the world of innovative drugs The biggest demand for innovative drugs is how to achieve commercialization In this regard, for the first time, 1 pharmaceutical network innovatively put forward the strategy of Omni channel commercialization platform 1 Pharmaceutical network should make use of its online and offline integrated medical and health platform to help pharmaceutical enterprises to cover drugstores, clinics, private hospitals, community hospitals, 3-6 hospitals and patients beyond the 1-2 urban hospitals and large chain drugstores, so as to provide complementary value-added services for pharmaceutical enterprises In addition to building platform support, 1 pharmaceutical network also proposed for the first time to build a decentralized academic promotion platform for medical representatives - Shizhen, which aims to promote pharmaceutical market education through professional content services At present, the website has successfully recruited 1000 medical representatives In addition, 1 drug network also launched the original research drug welfare plan for C-terminal, aiming to enable patients, enhance patients' drug compliance, and help pharmaceutical enterprises improve the accessibility of the original research drug through systematic operation of the whole process, such as doctor consultation, medication guidance, online follow-up, pharmacist service, etc.